There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC’s therapeutic agents that have shown the potential for progress in clinical practice. This review provides an overview of tyrosine kinase inhibitors targeting VEGF and KIT, BRAF and MEK inhibitors, TLR9 agonist, STAT3 inhibitors, and immune checkpoint blockers (PD1/PDL-1 inhibitors), for which recent advances have been reported. These new agents have the potential to provide benefits to CRC patients with unmet medical needs.

Emerging therapeutic agents for colorectal cancer / Nalli, M.; Puxeddu, M.; La Regina, G.; Gianni, S.; Silvestri, R.. - In: MOLECULES. - ISSN 1420-3049. - 26:24(2021), pp. 7463-7463. [10.3390/molecules26247463]

Emerging therapeutic agents for colorectal cancer

Nalli M.;Puxeddu M.;La Regina G.;Gianni S.;Silvestri R.
2021

Abstract

There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC’s therapeutic agents that have shown the potential for progress in clinical practice. This review provides an overview of tyrosine kinase inhibitors targeting VEGF and KIT, BRAF and MEK inhibitors, TLR9 agonist, STAT3 inhibitors, and immune checkpoint blockers (PD1/PDL-1 inhibitors), for which recent advances have been reported. These new agents have the potential to provide benefits to CRC patients with unmet medical needs.
2021
Anticancer agents; cancer; CRC; emerging targets
01 Pubblicazione su rivista::01a Articolo in rivista
Emerging therapeutic agents for colorectal cancer / Nalli, M.; Puxeddu, M.; La Regina, G.; Gianni, S.; Silvestri, R.. - In: MOLECULES. - ISSN 1420-3049. - 26:24(2021), pp. 7463-7463. [10.3390/molecules26247463]
File allegati a questo prodotto
File Dimensione Formato  
Nalli_Emerging_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 2.82 MB
Formato Adobe PDF
2.82 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1604509
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 14
social impact